Soligenix, Inc. Common Stock
SNGXSoligenix, Inc. is a biotechnology company focused on developing and commercializing innovative products in the areas of infectious disease, oncology, and gastrointestinal disorders. The company leverages its proprietary ThermoVax vaccine thermosensitive platform and other advanced technologies to develop therapies and vaccines, aiming to address unmet medical needs through research and development efforts.
Company News
Soligenix (NASDAQ: SNGX) announced it is applying for vaccine development funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for a Bundibugyo virus vaccine. The company, in collaboration with University of Hawaiʻi researchers, has developed thermostable filovirus vaccines that demonstrated up to 100% protection in non-human ...
Soligenix shares surged 72% after announcing its ThermoVax platform can rapidly develop a vaccine for Bundibugyo virus, addressing a WHO-declared public health emergency in the Democratic Republic of Congo. The company's thermostabilized vaccine technology demonstrated 100% protection in non-human primates and has FDA Orphan Drug Designations for...
Over 30 pharmaceutical companies are actively developing more than 30 pipeline drugs for cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma affecting the skin. Key players including Prescient Therapeutics, Innate Pharma, and others are advancing promising therapies with various mechanisms of action through clinical trials. The market i...
Over 90 pharmaceutical companies are actively developing more than 100 pipeline psoriasis drugs across various clinical stages. Key players including Takeda, Can-Fite BioPharma, Oruka Therapeutics, and others are advancing promising therapies with novel mechanisms of action such as TYK2 inhibitors and IL-23 inhibitors. Recent developments include...
Soligenix announced positive clinical results from a comparative study showing HyBryte™ (synthetic hypericin) demonstrated more rapid and robust treatment response compared to Valchlor® (mechlorethamine) for cutaneous T-cell lymphoma treatment. The study showed 60% of HyBryte™ patients achieved treatment success versus 20% of Valchlor® pati...
